320-OR: Cardiovascular Effectiveness of Empagliflozin in Patients with and without Cardiovascular Disease
Abstract
In the EMPA REG OUTCOME trial, empagliflozin (EMPA) reduced the risk of cardiovascular (CV) death, all-cause mortality, and hospitalization for heart failure (HHF) in patients with type 2 diabetes (T2D) and established CV disease (CVD). We assessed the CV effectiveness of EMPA in real-world T2D patients with and without CVD within EMPRISE, a study on the effectiveness, safety and healthcare utilization of EMPA, based on Medicare and 2 U.S....
Paper Details
Title
320-OR: Cardiovascular Effectiveness of Empagliflozin in Patients with and without Cardiovascular Disease
Published Date
Jun 1, 2021
Journal
Volume
70
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History